DNA Therapeutics is a privately-owned biopharmaceutical company dedicated to the development of our original siDNA^® (signal interfering DNA) technology platform and molecules, which interfere with DNA damage repair mechanisms, to fight treatment-resistant cancers.

Our lead molecule, Dbait, minics a DNA double strand break (DSB) to divert and disorganize the repair system responsible for recognizing and fixing DSBs on chromatins. The aim of Dbait treatment is to compromise the ability of cancer cells to repair the DSBs inflicted by traditional cancer therapies, thus overcomes radio-/chemo-resistance and greatly improves therapeutic outcome.

The proofs of concept of Dbait have been achieved in four human tumors xenografted onto nude mice by intratumoral or intraperitoneal injection in association with radiotherapy, and in spontaneous intestinal tumors in genetically engineered mice by oral administration in associated with chemotherapy. Biomarkers specific of Dbait's bioactivity have been identified and are under development.

Dbait will be first administered by local, then by systemic delivery. This is in line with our clinical development strategy focused at first making clear-cut demonstration of the efficacy of Dbait in the indications where the current standard of care treatment fails to control tumor progression, then extending to other major segments of oncology market.

Dbait is a prototype of a novel concept of molecular therapy applied to DNA repair pathway, at supra-molecular level (multi-protein complex targeting), by siDNA technology.

=> Fact sheet